相关实验视频

Updated: Jan 9, 2026

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

葡萄糖类-1受体激活剂对酒精消费的影响:系统性审查和元分析

Reza Eshraghi¹, Delaram J Ghadimi², Sara Montazerinamin³

¹Interventional Cardiology Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences (MUI), Iran.

EClinicalMedicine

|December 1, 2025

概括

类似葡萄糖-1受体激动剂 (GLP-1RA) 在患有酒精使用障碍 (AUD) 的人群中显著降低了酒精使用和相关危害. 这些药物,特别是塞马格卢提德和利拉格卢提德,在AUD管理方面表现有前途,特别是在并发症条件下.

科学领域:

药理学药理学是指药理学的学科.
成药物药物药物药物
代谢障碍代谢障碍代谢障碍

背景情况:

酒精使用障碍 (AUD) 是一个重大的全球健康挑战,复发率很高.
最初用于2型糖尿病和肥胖症的葡萄糖类-1受体激动剂 (GLP-1RA),正在研究它们降低酒精消费的潜力.
GLP-1 RAs可能会影响中央奖励通路,为AUD提供一种新的治疗途径.

研究的目的:

系统地审查和元分析GLP-1RA在减少酒精使用和相关结果方面的有效性现有证据.
评估GLP-1RA对AUDIT分数,酒精消费,复发率和与酒精有关的发病率的影响.
探索GLP-1RA对饮酒行为影响的潜在机制.

主要方法:

按照PRISMA指南进行了系统审查和元分析,包括随机对照试验 (RCT) 和观察性研究.
该搜索涵盖了从创立到2025年6月1日的所有数据库,重点关注有危险饮酒或AUD的成年人群.
主要结局是酒精使用障碍识别测试 (AUDIT) 成绩的变化;次要结局包括酒精消费,复发和生物标志物.

主要成果:

分析了14项研究 (n = 5,262,268) 涉及塞马格卢提德,利拉格卢提德和其他GLP-1RA.
观察到AUDIT分数的显著下降 (平均差异 -7.81分).
GLP-1 RA使用与减少酒精摄入量,减少饮酒日,减少渴望,降低复发率和减少与酒精有关的诊断有关,特别是在糖尿病或肥胖患者中使用塞马格卢提德和利拉格卢提德.

结论:

GLP-1 RAs,特别是Semaglutide和liraglutide,在减少酒精使用和相关危害方面表现出显著的有效性,AUDIT分数和消费量下降证明了这一点.
机械洞察力表明对渴望和奖励路径的调节,支持它们在AUD管理中潜在的重用.
需要进一步的大规模RCT来证实这些发现,并确定AUD的最佳治疗策略,特别是在具有并发性代谢疾病的个体中.

关键词:

酒精使用障碍使用障碍.作为GLP-1受体的激动剂.神经成像是一种神经成像.药物治疗药物治疗塞马格卢提德 (semaglutide) 是一种类型的

更多相关视频

Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer

Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer

Published on: November 15, 2024

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

Published on: January 29, 2017

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

CNS Depressants: Alcohol and Nicotine

CNS Depressants: Alcohol and Nicotine

Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...